Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a website help liver cancer patients care for themselves during chemoembolization?

NCT ID NCT07825519

Symptom relief Sponsor: University Medical Center Ho Chi Minh City (UMC) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for their first TACE at a hospital in Vietnam. Participants are randomly assigned to receive either routine education plus the web program or routine education plus printed materials. The study measures knowledge, self-care practices, and quality of life at the start and again one and three months after TACE.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an enhanced web-based health education program
What this could lead to
If it works, this could give patients with liver cancer a low-cost, easy-to-reach way to manage their own care and feel better during TACE treatment.
What could go wrong
The trial measures knowledge, self-care, and quality of life over three months, so it cannot show whether web education changes long-term outcomes. People who struggle with technology or have limited internet access may not benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

252 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Patients aged 18 years or older who are diagnosed with hepatocellular carcinoma (HCC) and are scheduled to undergo Transarterial Chemoembolization (TACE) for the first time at the Department of Hepatobiliary and Pancreatic Surgery, University Medical Center Ho Chi Minh City. * Patients who agree to participate in the study and provide informed consent. Exclusion Criteria: * • Patients with HCC scheduled to undergo TACE who have diagnosed cognitive impairment due to neurological disorders. * Patients who are unable to understand spoken Vietnamese. * Patients with language or hearing impairments that interfere with communication and participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - hepatocellular carcinoma Quality of life Self-care Tace(transcatheter arterial chemoembolization) Transarterial chemoembolization Web-based intervention

Contacts and locations

Locations

  • University Medical Center

    Ho Chi Minh City, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.